| Comprehensive transcriptional analysis of early-stage urothelial carcinoma J Hedegaard, P Lamy, I Nordentoft, F Algaba, S Høyer, BP Ulhøi, S Vang, ... Cancer cell 30 (1), 27-42, 2016 | 605 | 2016 |
| Genomic Profiling of MicroRNAs in Bladder Cancer: miR-129 Is Associated with Poor Outcome and Promotes Cell Death In vitro L Dyrskjøt, MS Ostenfeld, JB Bramsen, AN Silahtaroglu, P Lamy, ... Cancer research 69 (11), 4851-4860, 2009 | 461 | 2009 |
| Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties MS Ostenfeld, DK Jeppesen, JR Laurberg, AT Boysen, JB Bramsen, ... Cancer research 74 (20), 5758-5771, 2014 | 312 | 2014 |
| miR-145 induces caspase-dependent and-independent cell death in urothelial cancer cell lines with targeting of an expression signature present in Ta bladder tumors MS Ostenfeld, JB Bramsen, P Lamy, SB Villadsen, N Fristrup, ... Oncogene 29 (7), 1073-1084, 2010 | 179 | 2010 |
| Mutational context and diverse clonal development in early and late bladder cancer I Nordentoft, P Lamy, K Birkenkamp-Demtröder, K Shumansky, S Vang, ... Cell reports 7 (5), 1649-1663, 2014 | 171 | 2014 |
| The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer SB Villadsen, JB Bramsen, MS Ostenfeld, ED Wiklund, N Fristrup, S Gao, ... British journal of cancer 106 (2), 366-374, 2012 | 147 | 2012 |
| Transcriptome-wide profiles of circular RNA and RNA-binding protein interactions reveal effects on circular RNA biogenesis and cancer pathway expression TLH Okholm, S Sathe, SS Park, AB Kamstrup, AM Rasmussen, A Shankar, ... Genome medicine 12, 1-22, 2020 | 132 | 2020 |
| Expression of TIP60 (tat‐interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment‐specific outcome of localised invasive bladder cancer JR Laurberg, AS Brems‐Eskildsen, I Nordentoft, N Fristrup, T Schepeler, ... BJU international 110 (11c), E1228-E1236, 2012 | 107 | 2012 |
| Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer N Fristrup, BP Ulhøi, K Birkenkamp-Demtröder, F Mansilla, ... The American journal of pathology 180 (5), 1824-1834, 2012 | 94 | 2012 |
| High Expression of Karyopherin-α2 Defines Poor Prognosis in Non–Muscle-Invasive Bladder Cancer and in Patients with Invasive Bladder Cancer Undergoing Radical Cystectomy JB Jensen, PP Munksgaard, CM Sørensen, N Fristrup, ... European urology 59 (5), 841-848, 2011 | 87 | 2011 |
| Multicenter validation of Cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle–invasive bladder cancer N Fristrup, K Birkenkamp-Demtröder, T Reinert, M Sanchez-Carbayo, ... The American journal of pathology 182 (2), 339-349, 2013 | 83 | 2013 |
| Low ANXA10 expression is associated with disease aggressiveness in bladder cancer PP Munksgaard, F Mansilla, AS Brems Eskildsen, N Fristrup, ... British journal of cancer 105 (9), 1379-1387, 2011 | 54 | 2011 |
| High frequency of tumor cells with nuclear Egr-1 protein expression in human bladder cancer is associated with disease progression FL Egerod, A Bartels, N Fristrup, M Borre, TF Ørntoft, MB Oleksiewicz, ... BMC cancer 9, 1-8, 2009 | 44 | 2009 |
| A high resolution genomic portrait of bladder cancer: correlation between genomic aberrations and the DNA damage response T Schepeler, P Lamy, V Hvidberg, JR Laurberg, N Fristrup, T Reinert, ... Oncogene 32 (31), 3577-3586, 2013 | 39 | 2013 |
| Folic acid reduces mucositis in metastatic renal cell carcinoma patients: a retrospective study N Fristrup, F Donskov Clinical genitourinary cancer 17 (4), 254-259, 2019 | 7 | 2019 |
| Management of renal cell carcinoma: promising biomarkers and the challenges to reach the clinic I Lyskjær, L Iisager, CT Axelsen, TK Nielsen, L Dyrskjøt, N Fristrup Clinical Cancer Research 30 (4), 663-672, 2024 | 5 | 2024 |
| Multicenter randomized trial of deferred cytoreductive nephrectomy in synchronous metastatic renal cell carcinoma receiving checkpoint inhibitors: the NORDIC-SUN-Trial L Iisager, J Ahrenfeldt, F Donskov, B Ljungberg, A Bex, L Lund, I Lyskjær, ... BMC cancer 24 (1), 260, 2024 | 3 | 2024 |
| Moderne endoskopische Bildgebungsverfahren für das Urothelkarzinom der Harnblase MC Kriegmair, M Ritter, MS Michel, C Bolenz Aktuelle Urologie 48 (04), 296-305, 2017 | 2 | 2017 |
| TOX3 (TNRC9) over expression in bladder cancer cells decreases cellular proliferation and triggers an interferon-like response K Birkenkamp-Demtroder, F Mansilla, L Dyrskjøt, K Thorsen, N Fristrup, ... J Mol Biomark Diagn 4 (140), 2, 2013 | 2 | 2013 |
| KIDNEY-PAGER: analysis of circulating tumor DNA as a biomarker in renal cancer-an observational trial. Study protocol L Iisager, J Ahrenfeldt, AK Keller, TK Nielsen, N Fristrup, I Lyskjær Acta Oncologica 63 (1), 51-55, 2024 | 1 | 2024 |
Lars DyrskjøtProfessor of Molecular Medicine, Aarhus University在 clin.au.dk 的电子邮件经过验证
